Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Selective CBP/EP300 Bromodomain Inhibitors: Novel Epigenetic Tools to Counter TNF-α-Driven Inflammation

5 Jun 2025

Abstract excerpt

High Resolution Image Download MS PowerPoint Slide Tumor necrosis factor α (TNF-α) is a central driver of inflammation in autoimmune conditions such as Crohn’s disease and rheumatoid arthritis (RA). Targeting epigenetic regulators involved in cytokine expression holds therapeutic promise, yet the precise role of the CBP/EP300 bromodomains (BRDs) in modulating immune responses remains poorly understood. Here, we...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Histone Deacetylase Inhibitors Research
Share to Peptidase Inhibition and Analysis
Share to Protein Degradation and Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40575322
DOI: 10.1021/jacsau.5c00085

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Selective CBP/EP300 Bromodomain Inhibitors: Novel Epigenetic Tools to Counter TNF-α-Driven InflammationPMID 40575322Read ↗

Disrupting Acetyl-Lysine Recognition: Progress in the Development of Bromodomain InhibitorsSemantic proximity Read ↗

CBP/P300 Inhibition Impairs CD4+ T Cell Activation: Implications for Autoimmune DisordersSemantic proximity Read ↗

Targeting bromodomain-containing proteins: research advances of drug discoverySemantic proximity Read ↗

Ameliorative effect of a quinazoline-based bromodomain inhibitor, CN210, on experimentally-induced Crohn’s disease-like murine ileitis via inhibition of inflammatory cytokine expressionSemantic proximity Read ↗

Discovery of Exceptionally Potent, Selective, and Efficacious PROTAC Degraders of CBP and p300 ProteinsSemantic proximity Read ↗

N4BP1 is dimerization-dependent linear ubiquitin reader regulating TNFR1 signalling through linear ubiquitin binding and Caspase-8-mediated processingSemantic proximity Read ↗

Design and Synthesis of a Highly Selective and In Vivo-Capable Inhibitor of the Second Bromodomain of the Bromodomain and Extra Terminal Domain Family of ProteinsSemantic proximity Read ↗

Analysis of the RelA:CBP/p300 Interaction Reveals Its Involvement in NF-κB-Driven TranscriptionSemantic proximity Read ↗

CBP/p300 Drives the Differentiation of Regulatory T Cells through Transcriptional and Non-Transcriptional MechanismsSemantic proximity Read ↗

STAT1 epigenetically regulates LCP2 and TNFAIP2 by recruiting EP300 to contribute to the pathogenesis of inflammatory bowel diseaseSemantic proximity Read ↗

The histone acetyl transferases CBP and p300 regulate stress response pathways in synovial fibroblasts at transcriptional and functional levelsSemantic proximity Read ↗

Bromodomain protein inhibition: a novel therapeutic strategy in rheumatic diseasesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.